Grünenthal Press Releases 2012

Grünenthal to present its Tamper Resistant Formulation Technology INTAC® at the Meeting & Exposition of the Controlled Release Society

Bedminster, NJ – July 12, 2012. This year’s 39th Annual Meeting and Exposition of the Controlled Release Society (CRS) will take place in Quebec City, Canada from July 15-18, 2012. Grünenthal’s participation in the event will include a booth exhibition as well as hosting an interactive Releasing Technology Workshop.

The annual CRS conference offers opportunities to learn about the most recent advancement in drug delivery science, one of which is Grünenthal’s tamper resistant technology, INTAC®. INTAC® helps safeguard the intended use of oral extended release products while providing patients the same effective drug delivery as conventional formulations. Specifically, for prescription opioids, the application of INTAC® technology is an efficient means to combat unintended and intended tamper-based drug misuse and abuse.

In the course of the Releasing Technology Workshop section, Grünenthal will offer an interactive, educational seminar that is scheduled for Sunday, July 15, 2012 from 11:30-12:30p.m. Grünenthal will provide insight into applications of its tamper resistant technology, development of the technology, manufacturing opportunities as well as description of its properties. At the INTAC® information booth (#128), Grünenthal experts will discuss and present more details of the innovative INTAC® technology. Booth visitors are invited to personally experience the outstanding crush resistant properties of INTAC® tablets in attempting to smash the tablets by hammer strokes.

About INTAC®
Tablets produced using INTAC® technology are designed to resist crushing even by heavy hammer blows, foiling the key step in most forms of opioid abuse. In addition to their high breaking strength tablets produced by the INTAC® process form a gel in solutions that cannot be readily injected or snorted, and they resist extraction of active drug by a wide range of solvents. The mechanical stability is created by the combination of specific excipients together with a unique manufacturing process. INTAC® is the leading tamper resistance technology now in use, with already two FDA-approved products available in the United States. INTAC® manufacturing is established at commercial scale in the US and Europe. The technology is available for licensing to interested companies for various opportunities. Companies licensing INTAC® technology for their products are following a proven approach with a track record of regulatory approval. For more information about INTAC® please visit

About Grünenthal
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grünenthal is one of the last five research-oriented pharmaceutical corporations with headquarters in Germany which sustainably invests in research and development. These investments amounted to about 25 percent of revenues in 2011. Grünenthal’s research and development strategy concentrates on select fields of therapy and state-of-the-art technologies. We focus on the intensive search for new ways to treat pain better, more effectively and with fewer side-effects than before. Altogether, the Grünenthal Group has affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries and today approximately 4,200 employees are working for the Grünenthal Group worldwide. In 2011, Grünenthal achieved revenues of €947 mn.


Grünenthal USA, Inc.
Alexander Kraus, PhD
Vice President
Program Management Global TRF Business
One Pluckemin Way
Bedminster, NJ 07921
Phone: +1 908-745-2271
Grünenthal GmbH, Germany
Kai Strothmann, PhD
Phone: +49 241 569 1796

Frank Schoenrock
Vice President Corporate Communications
Phone: +49 241 569 1568

 Grünenthal GmbH, 52099 Aachen, Germany,